7 Best Peptides for Pulmonary Hypertension

What to Know Before Choosing a Peptide for Pulmonary Hypertension

Pulmonary hypertension is a serious, progressive condition involving elevated blood pressure inside the arteries that carry blood from the right side of the heart to the lungs. The driving forces behind it include blood vessel narrowing, chronic inflammation, abnormal cell growth inside artery walls, and a deficiency in the body's natural vasodilatory signals. Standard approved treatments target those same pathways using non-peptide drugs, and that is exactly why researchers have been studying peptides here: several naturally occurring peptides directly activate the signaling cascades that malfunction in pulmonary hypertension, making them a scientifically rational area of investigation even though none has yet reached routine clinical use.

Every compound in this list earned its slot by one standard: people use it or are actively discussing it for pulmonary hypertension, whether in published clinical research, preclinical investigation, or the broader research and patient community. That standard is deliberately broad. FDA approval, robust human trial data, and commercial availability are not the filter here. A compound with only animal model data and community interest still belongs, as long as its evidence is stated plainly rather than papered over. The honest state of each compound's evidence is described in plain language inside its own entry.

The numbers in front of each compound are a spine for the list, not a verdict. The ordering reflects how prominently each compound appears in research and in real-world or research-community use for this specific goal. It is not a recommendation of one compound over another, and it is not a clinical protocol. Pulmonary hypertension requires careful hemodynamic management under physician supervision. What this guide offers is an honest map of the compounds researchers have focused on, so readers can orient the conversation with their care team and explore further inside the app.

1. Aviptadil: The Most Clinically Studied Pulmonary Peptide

Aviptadil is the synthetic form of vasoactive intestinal peptide, a 28-amino acid signaling molecule that occurs naturally in the body and plays a central role in regulating blood vessel tone in the lungs. The reason researchers pursued it for pulmonary hypertension is almost elegantly simple: people with idiopathic pulmonary arterial hypertension are consistently found to be deficient in VIP in both their serum and their lung tissue. Restoring what the body is already missing is a different therapeutic logic than introducing a foreign compound, and that rationale drove the clinical work that followed.

In an early human study involving eight patients with primary pulmonary hypertension, inhaled aviptadil reduced mean pulmonary artery pressure, increased cardiac output, and raised mixed venous oxygen saturation, all meaningful hemodynamic improvements, with no side effects reported. A later tolerability study using a single inhaled dose in a group of patients with moderate to severe pulmonary hypertension confirmed the drug was well tolerated, acted as a pulmonary-selective vasodilator, and tended to improve oxygenation in patients with chronic lung disease, without affecting systemic blood pressure. A double-blind, randomized, placebo-controlled dose-finding trial registered in Europe then evaluated single and repeated inhalation in pulmonary arterial hypertension patients, assessing hemodynamic effects, clinical efficacy, and safety. Phase II trials in primary pulmonary hypertension showed improved hemodynamics and improved exercise capacity, with mean pulmonary artery pressure reductions documented across the program.

The inhalation route is deliberate. Delivering aviptadil directly to the lungs concentrates the effect at the target and avoids the systemic effects that would come from injection. The mechanism runs through a pair of receptors called VPAC1 and VPAC2, found on pulmonary vascular smooth muscle cells. When aviptadil binds them, it triggers a cascade that raises levels of cyclic AMP inside the smooth muscle cell. Think of cyclic AMP here as the internal messenger that flips the switch from contraction to relaxation. Higher cyclic AMP activates protein kinase A, which then inhibits the mechanism keeping smooth muscle contracted, and the pulmonary arteries widen. Aviptadil also suppresses a pathway called RhoA and Rho-kinase, which drives the abnormal smooth muscle cell growth that physically thickens and remodels pulmonary artery walls over time. Vasodilation and anti-remodeling through two distinct actions in the same molecule is what made aviptadil the most thoroughly investigated peptide candidate in this space. It is not FDA-approved for pulmonary hypertension and remains the compound with the most human clinical data of any peptide in this field.

2. Pemziviptadil: The Long-Acting VIP Successor in Active Trials

Pemziviptadil, developed under the code name PB1046, is a next-generation analog of aviptadil engineered for a longer duration of action. Where natural VIP degrades rapidly in circulation, pemziviptadil is chemically stabilized to extend its activity, which addresses one of the main practical limitations of the original molecule for ongoing therapeutic use.

Human trial data exists, though it is still accumulating. A pilot study in three patients with pulmonary arterial hypertension found the compound was safe, with no serious adverse events. Case-level data from the pilot showed improvements in mean pulmonary artery pressure and reduced resistance to blood flow through the lungs over an 18-month period, with those benefits maintained for up to three months after treatment ended. That durability is notable and is one reason the program progressed to a Phase 2b trial involving up to 63 adult pulmonary arterial hypertension patients, evaluating safety, vital signs, mean pulmonary artery pressure, and physical function. An open-label extension arm extended follow-up further.

The mechanism mirrors aviptadil: VPAC1 and VPAC2 receptor agonism, cyclic AMP elevation, and smooth muscle relaxation, with the added benefit of a longer pharmacological window per dose. Pemziviptadil is investigational and not FDA-approved. It represents the most clinically active development program in peptide-based pulmonary hypertension research as of 2026.

3. CNP-53: A Natriuretic Peptide Derivative Targeting Arterial Pressure

CNP-53 is a derivative of C-type natriuretic peptide, a member of a family of endogenous signaling molecules the body uses to regulate blood vessel tone, fluid balance, and cell growth. Natriuretic peptides bind to specific receptors on blood vessel cells, trigger production of cyclic GMP (a second messenger that works through a parallel but distinct pathway from the cyclic AMP route VIP uses), and through that signal cause smooth muscle relaxation, inhibit abnormal cell proliferation, and reduce fibrotic thickening of vessel walls.

In rodent models of severe pulmonary arterial hypertension, CNP-53 significantly suppressed right ventricular systolic pressure and ventricular hypertrophy ratios, two of the key measurements researchers use to track disease severity. The compound also showed additive benefit when combined with existing pulmonary arterial hypertension therapies, which matters practically because people with pulmonary hypertension are nearly always on established treatment regimens. A compound that works alongside current therapies rather than against them is considerably more translatable to real clinical settings than one that requires replacing existing treatment.

CNP-53 operates through the GC-B receptor, formally called guanylyl cyclase B or NPR-B, which sits on endothelial cells in the pulmonary vasculature. Activation produces cyclic GMP, which flows downstream to relax smooth muscle, suppress abnormal proliferation, and reduce fibrotic thickening in pulmonary artery walls. The natriuretic peptide family as a whole is regarded as a promising research avenue in pulmonary hypertension, and CNP-53 is among the more recently studied derivatives with published preclinical results from rodent severe PAH models. It has not entered human clinical trials.

4. Netrin-1 Derived Peptides: Novel Analogs Targeting Nitric Oxide

Netrin-1 is a guidance protein best known for its role in the developing nervous system, but it also plays a role in blood vessel biology. Two modified analogs, called V1S and V1C, were developed specifically to be more stable and more potent than native netrin-1 itself, and both have attracted research attention in pulmonary hypertension because of how they influence nitric oxide signaling.

In hypoxia-induced mouse models of pulmonary hypertension, these peptides reduced mean pulmonary artery pressure and right ventricular systolic pressure to below baseline levels, not merely slowing the disease but bringing measured pressures back toward normal. The analogs outperformed native netrin-1 in head-to-head comparisons within the same models. The mechanism runs through a receptor called DCC, which activates ERK1/2, a signaling protein that in turn stimulates endothelial nitric oxide synthase. More active eNOS means more nitric oxide production, and nitric oxide is the body's primary endogenous signal for relaxing blood vessel smooth muscle. The peptides also attenuate oxidative stress in the pulmonary vasculature, contributing a complementary protective effect on the endothelial cells that line pulmonary artery walls.

Netrin-1 derived peptides are preclinical compounds with no published human clinical trial data. Their research footprint in the pulmonary hypertension scientific literature is growing, and they appear regularly in research summaries of compounds being studied for this condition. They are discussed in the research community as a novel mechanistic approach to restoring nitric oxide signaling, operating through a receptor pathway distinct from the eNOS-stimulating approaches used by some of the other compounds in this list.

5. BPC-157: Preclinical Endothelial Repair Data, No Human PH Trials

BPC-157, short for Body Protection Compound-157, is a synthetic 15-amino acid peptide derived from a protective protein found in gastric juice. It is most widely discussed in the peptide community for gut healing, tendon repair, and tissue recovery, areas where its animal research record is extensive. Its relevance to pulmonary hypertension comes from a separate body of preclinical work that has attracted attention in research summaries and, more recently, in community discussions about peptides and respiratory conditions.

In rat models using monocrotaline to induce pulmonary arterial hypertension, BPC-157 prevented the development of PAH and prevented right ventricular failure, the downstream consequence of chronically elevated pulmonary artery pressure. Notably, the research reported that it normalized pulmonary arterial pressure even in animals with established, advanced-stage disease, which suggests potential utility after the condition has progressed rather than only prophylactically. No human clinical trial has been published examining BPC-157 in pulmonary hypertension as of 2026. What exists is animal model data and the research community's interest in understanding whether those findings translate.

The mechanism proposed for these effects involves the VEGFR2-FAK signaling pathway. VEGFR2 acts as a receptor on the surface of blood vessel lining cells that functions as an on-switch for vascular repair processes. BPC-157 appears to activate that pathway and separately to restore function of endothelial nitric oxide synthase, the enzyme responsible for producing nitric oxide in pulmonary vessel walls. Endothelial dysfunction, meaning the impaired ability of blood vessel lining cells to produce nitric oxide and regulate tone, is a central feature of pulmonary arterial hypertension, which gives BPC-157's endothelial rescue findings their theoretical relevance to this condition.

In the broader research and biohacking community, BPC-157 is one of the most widely discussed peptides across a range of goals, but its use specifically for pulmonary hypertension sits firmly in the experimental and research-interest category. No community protocols involving BPC-157 for PAH have been widely reported. Its inclusion here reflects its standing in 2026 research summaries of peptides investigated for this condition and the animal evidence that has drawn research attention.

6. CAR Peptide: A Vascular Homing Research Compound

The CAR peptide, named for its amino acid sequence CARSKNKDC, takes a conceptually different approach from the other compounds in this list. Rather than trying to relax blood vessels broadly or restore a deficient signaling molecule systemwide, the CAR peptide is designed as a vascular homing peptide: it selectively homes to hypertensive pulmonary arteries rather than healthy ones, which in principle allows it to concentrate its effects where the disease is active.

In rat and mouse preclinical models, the CAR peptide improved survival and hemodynamics in pulmonary hypertension. It also showed additive benefit when combined with two established PAH drugs, suggesting it could complement rather than replace existing treatment approaches. A finding of particular interest for potential translation is that CAR receptor expression was demonstrated in human cells, not only in rodent models, which is an early signal that the homing mechanism may function in human pulmonary vasculature.

No published human clinical trial data exists for the CAR peptide in pulmonary hypertension as of 2026. It is discussed in the pulmonary hypertension research literature and in research-focused community spaces as a novel delivery concept with preclinical support. Its targeting logic has drawn interest from researchers exploring how to improve specificity of drug delivery in pulmonary hypertension, a condition where systemic vasodilation is often an unwanted side effect of therapies aimed at the pulmonary circulation. Its evidence base remains entirely preclinical.

7. Chonluten: A Bronchopulmonary Peptide Bioregulator

Chonluten is a short tripeptide that falls within a family of regulatory peptides developed in Russia and Eastern Europe, where the broader class has been studied for cytoprotective and tissue-regulatory effects across organ systems. Chonluten's proposed target is bronchopulmonary tissue, meaning the cells and structures of the lungs and airways, which is the basis for its relevance to any discussion of pulmonary conditions.

The honest picture for Chonluten and pulmonary hypertension is this: no clinical trial data and no dedicated preclinical study focused on pulmonary arterial pressure reduction has been published for this compound as of 2026. What exists is a theoretical rationale based on its class membership as a bronchopulmonary peptide bioregulator. Short peptide bioregulators in this family are understood to support cytoprotection in lung tissue and to modulate gene expression in pulmonary cells, and both of those mechanisms are broadly relevant to pulmonary hypertension's pathophysiology, which involves endothelial injury, inflammatory dysregulation, and impaired cell signaling within pulmonary vascular tissue.

Chonluten appears in research and community discussions about peptides for lung health and pulmonary conditions, which is why it earns an entry here under the standard that guides this list: people discuss it in the context of pulmonary health, and that warrants an honest account rather than silent omission. It is available in some Eastern European markets and classified as a research peptide in the United States. Anyone approaching Chonluten for pulmonary hypertension is working entirely from theoretical reasoning and general lung-protective class data, with no condition-specific evidence to draw on. That does not make the discussion illegitimate, but it does define exactly where the current evidence stands.

How These Peptides Compare

Frequently Asked Questions

Are any peptides approved to treat pulmonary hypertension?

No traditional small peptide is currently FDA-approved as a treatment for pulmonary hypertension. The most recently approved drug for pulmonary arterial hypertension, sotatercept, is a fusion protein targeting a different biological pathway and is not a small peptide in the conventional sense. All of the peptides discussed in this guide are either investigational, studied only in animal models, or discussed in the research community without formal trial support.

How does aviptadil differ from the other peptides on this list?

Aviptadil stands apart because it is the only peptide in this field with published randomized, controlled human trial data showing actual reductions in pulmonary artery pressure in people with the condition. The other compounds are in earlier-stage human trials, studied only in animal models, or present in research discussion without clinical trial data. That distinction is why aviptadil leads the list by prominence in the research, and it is the relevant frame for evaluating the strength of the case for each compound.

Is BPC-157 being used by patients with pulmonary hypertension?

Not in any organized or widely reported way. BPC-157 appears in 2026 research summaries of peptides investigated for pulmonary hypertension based on its preclinical findings in rat models, but no community protocols or patient reports of BPC-157 use specifically for this condition have been broadly published. Its general research community presence is substantial across other goals, but its use for pulmonary hypertension specifically is in the experimental and research-interest category only, with no human trial data to draw on.

Can people with pulmonary hypertension safely explore peptides alongside their current medications?

This is a question that belongs entirely with a qualified physician who knows the individual's full treatment picture. Pulmonary hypertension management depends on carefully calibrated hemodynamic targets, and any compound that affects blood vessel tone or cardiac output in the pulmonary circulation interacts with that balance. None of the peptides in this guide are used as part of standard clinical care, and safety data specific to these compounds in human pulmonary hypertension is either limited or entirely absent.

Why do some peptides on this list have so little published data?

Pulmonary hypertension is a rare condition, which makes large-scale clinical trials expensive and slow to complete. Much of the peptide research in this field starts in animal models precisely because pulmonary hypertension can be induced reliably in rats and mice, giving researchers a way to test a mechanism before committing to human trials. That means the field has a considerably larger body of animal data than human data, and compounds like Chonluten or the CAR peptide appear in research and community discussions without yet having the human trial record that aviptadil has accumulated over decades of investigation.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for pulmonary hypertension in one place.